GSK’227 is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. The Food and Drug Administration (FDA) has ...
A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...
Antibody-drug conjugates (ADCs) are transforming oncology by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. Yet, developing effective ADCs requires overcoming ...
Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...
BEIJING & BOSTON--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today ...
Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab deruxtecan this winter—AstraZeneca is placing a big ...
HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death. "I don't think I need to convince anyone here that we need to discover new ...
News Medical on MSN
Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias
Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...
AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...
ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...
The pharmaceutical industry’s antibody-drug conjugate( ADC) deal spree continues. AbbVie says it will buy ImmunoGen for about $10 billion, adding to a series of multi-billion dollar acquisitions built ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback